Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Omar Kayaleh"'
Autor:
Sherise Rogers, Ryan Thomas, Brain Ramnaraign, Ilyas Sahin, Jesus Fabregas, Karen Russell, Steven Hughes, Ibrahim Nassour, Kathyrn Hitchcock, Omar Kayaleh, Anita Turk, Ji-Hyun Lee, David DeRemer, Carmen Allegra, Thomas George
Publikováno v:
Cancer Research. 83:2186-2186
Background: Pancreatic cancer portends a very poor prognosis. It is the third leading cause of cancer deaths in the United States. African Americans have a 50- 90% increased incidence of pancreatic cancer in comparison to other racial groups. 20% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea4a212e6e2a02cc945c0e5a08daec74
https://doi.org/10.1158/1538-7445.am2023-2186
https://doi.org/10.1158/1538-7445.am2023-2186
Autor:
Sherise Rogers, Ryan Thomas, Brian Ramnaraign, Ilyas Sahin, Jesus Fabregas, Karen Russell, Steven Hughes, Ibrahim Nassour, Kathryn Hitchcock, Omar Kayaleh, Anita Turk, Ji-Hyun Lee, David DeRemer, Carmen Allegra, Thomas George
Publikováno v:
Cancer Research. 82:B037-B037
Background: Pancreatic cancer portends a very poor prognosis. It is the third leading cause of cancer deaths in the United States. African Americans have a 50- 90% increased incidence of pancreatic cancer in comparison to other racial groups. 20% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::22db16a9cbef2b47cccb4d8c8ca0cdbe
https://doi.org/10.1158/1538-7445.panca22-b037
https://doi.org/10.1158/1538-7445.panca22-b037
Autor:
E. Claire Dees, Jaafar Bennouna, A. Craig Lockhart, Bin Zhang, Radka Obermannova, Petr Zatloukal, Omar Kayaleh, Antoine Adenis, Angela DeMichele, Bohuslav Melichar, Claudio Dansky Ullmann, Claudia Schusterbauer
Publikováno v:
The Lancet Oncology. 16:395-405
Summary Background Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. We aimed to investigate the safety and activity of single-agent alisertib in patients with predefined types of advanced solid tumours. Methods We did a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2068c7456fde0e382c5f289b7612aea4
https://doi.org/10.1016/s1470-2045(15)70051-3
https://doi.org/10.1016/s1470-2045(15)70051-3
Autor:
Jayne Gurtler, Andrew H. Ko, Terry Katz, Mark Keaton, Eric K. Rowinsky, Hagop Youssoufian, Omar Kayaleh, Heinz-Josef Lenz, Shaila Ballal, Karel Dicke
Publikováno v:
Investigational New Drugs. 30:1597-1606
The purpose of this study was to assess the efficacy and safety of bevacizumab plus cetuximab with or without gemcitabine in patients with advanced pancreatic adenocarcinoma. Patients with locally advanced or metastatic pancreatic adenocarcinoma, pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::666f34b0c46600181d0d6989c036e6b9
https://doi.org/10.1007/s10637-011-9691-8
https://doi.org/10.1007/s10637-011-9691-8
Autor:
Gregory K. Pennock, Nikita Shah, Julio Hajdenberg, Jennifer E. Tseng, Clarence H. Brown, Omar Kayaleh, Said Baidas
Publikováno v:
American Journal of Lifestyle Medicine. 3:337-348
Despite evidence that cancer death rates in the United States are declining, the absolute number of new cancers and cancer deaths continues to increase, and there is clear evidence that certain human behaviors are influencing these increases. The 4 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::98d372fdbdce10f526d48757bc5c8a29
https://doi.org/10.1177/1559827609334983
https://doi.org/10.1177/1559827609334983
Autor:
Omar Kayaleh, Heinz-Josef Lenz, I. Y. Gong, Cathryn Rankin, Charles D. Blanke, Syma Iqbal, Abby B. Siegel, Kenneth C. Micetich, Anthony B. El-Khoueiry
Publikováno v:
British Journal of Cancer
Background: Gallbladder cancers and cholangiocarcinomas make up a heterogenous group of tumours with a poor prognosis in advanced stages. On the basis of evidence of dysregulation of the epidermal growth factor receptor, vascular endothelial growth f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12b6e692a9b149dcce6b11d88f7203db
https://pubmed.ncbi.nlm.nih.gov/24423918
https://pubmed.ncbi.nlm.nih.gov/24423918
Publikováno v:
Current medicinal chemistry. 19(22)
Pancreatic cancer is an aggressive malignancy with poor prognosis. Pancreatic adenocarcinoma is one of the leading causes of cancer-related deaths in the United States. Due to the aggressive nature of this malignancy, there is a serious concern for i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e43a848f3bd927b306efcef59af3f61
https://pubmed.ncbi.nlm.nih.gov/22725697
https://pubmed.ncbi.nlm.nih.gov/22725697
Publikováno v:
Clinical Cancer Research. 21:A03-A03
Cancer treatment is complicated when patients develop resistance to standard therapies. Hence, developing strategies to address resistance to chemo therapy and improving therapeutic efficiency is of great importance in treating cancer successfully. R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c535e866e4fcf4f5839eec815cc30b9
https://doi.org/10.1158/1557-3265.pms14-a03
https://doi.org/10.1158/1557-3265.pms14-a03
Autor:
Omar Kayaleh, Mamoru Shoji, Riyaz Basha, Bassel F. El-Rayes, Ganji Purnachandra Nagaraju, Sarah F. Connelly, Umesh T. Sankpal
Publikováno v:
Cancer Research. 74:4216-4216
Tolfenamic acid (TA), a non-steroidal anti-inflammatory drug is known to inhibit human cancer cells and mouse tumor growth in some cancer models. TA is known to target the transcription factor, specificity protein1 (Sp1) that mediates the expression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::490bec45e4ecb30dbb8519c950dad2ae
https://doi.org/10.1158/1538-7445.am2014-4216
https://doi.org/10.1158/1538-7445.am2014-4216